Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

CTS-1027

Catalog No: tcsc0281

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Specifications

CAS No:
193022-04-7

Formula:
$C_{19}H_{20}ClNO_6S$

Pathway:
Metabolic Enzyme/Protease

Target:
MMP

Purity / Grade:
>98%

Solubility:
10 mM in DMSO

Alternative Names:
Ro 1130830;RS 130830

Observed Molecular Weight:
425.88

Product Description

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

CTS-1027 is a potent small molecule inhibitor of **MMPs**, with **IC_{50}**s of 0.3 nM, 0.5 nM for **MMP2**, **MMP13**, respectively, and has > 1,000 fold selectivity over MMP1.

IC50 & Target: IC50: 0.2 nM (MMP2), 0.5 nM (MMP13), 0.7 nM (MMP12), 0.9 nM (MMP8), 9.5 nM (MMP3), 15 nM (MMP14)

In Vivo: CTS-1027 significantly reduces the hepatocyte apoptosis, features of cholestatic liver injury, amd markers of hepatic fibrogenesis in the BDL mouse. CTS-1027 improves overall animal survival following 14 days of BDL in mice[1]. In male animals treated for 8 weeks the terminal plasma concentration of RS-130830 is 311±45 nM. Treatment of male mice with RS-130830 for 8 weeks causes an 89% increase in plasma triglyceride concentration, but there is no corresponding effect in female mice treated for 12 weeks. The plaque lipid content of animals receiving RS-130830 is increased by 81% at 12 weeks, and increased by 41% at 16 weeks[2].